Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Isis Pharmaceuticals, Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 80% |
| Gastrointestinal Pharmaceuticals: Technologies and Markets | Sep 2009 | £3,065 | 71% |
| Alnylam Pharmaceuticals, Inc – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 69% |
| U.S. Market for Gastrointestinal Pharmaceuticals | Sep 2005 | £2,760 | 69% |
| Obesity - Pipeline Review H2 2011 |
Sep 2011 | £315 | 67% |
| Ribonucleic Acid (RNA) Therapeutics Strong Potential to Address Unmet Needs in Pharma |
Feb 2010 | £2,215 | 66% |
| Prostate Cancer Therapeutics | Apr 2009 | £2,500 | 65% |
| Xenon Pharmaceuticals Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 65% |
| Prostate Cancer BRIC Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 64% |
| Achaogen Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 63% |
| Type 2 Diabetes - Pipeline Review H2 2011 |
Sep 2011 | £315 | 63% |
| Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 62% |
| Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 62% |
| Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 61% |
| Prostate Cancer – UK Drug Forecasts and Treatment Analysis to 2020 |
Nov 2010 | £1,895 | 61% |
| Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 61% |
| Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020 |
Nov 2010 | £1,895 | 61% |
| Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020 |
Dec 2010 | £1,895 | 61% |
| North America In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012 | Jan 2009 | £1,895 | 60% |
| United States in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
Apr 2009 | £1,580 | 59% |
| Diabetes - Pipeline Review H2 2011 |
Oct 2011 | £315 | 59% |
| Elan Corporation, plc – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 58% |
| Geron Corporation – Product Pipeline Review H2 2011 |
Oct 2011 | £315 | 57% |
| Biosensors in Medical Diagnostics | Jan 2011 | £2,845 | 55% |
| Neurodegenerative Drugs | Apr 2010 | £2,500 | 55% |
| Prostate Cancer Therapeutics A Global Market Perspective |
Nov 2009 | £1,895 | 55% |
| Diabetes, Metabolic Syndrome and Cardiovascular Disease | Apr 2009 | £2,150 | 53% |
| Array BioPharma Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 53% |
| Biotech M&A and Licensing Strategies Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines |
Apr 2011 | £2,215 | 52% |
| Cancer Profiling and Pathways Technologies and Global Markets |
Sep 2010 | £3,065 | 48% |
